These High-Performance Skis Are Made Out Of Algae
After biotech startup Checkerspot created plastic derived from microalgae, outdoor recreation products seemed like a perfect test for new compounds that replicate the properties of petroleum-based plastics. “We’re leveraging biotechnology to create new building blocks,” says cofounder and CEO (and skier) Charles Dimmler.
Different Funds| December 18, 2020
Different’s DeepTech Investing Report
Different’s DeepTech Investing Report is a landmark review of the state of advanced technology investing — the domain of atoms + bits, of science-driven and research-fueled innovation. From government and foundation grants to venture capital and Wall Street, the report lays out the history, challenges, and opportunities for DeepTech investment.
Cytovale | December 17, 2020
Cytovale™ Receives Distinguished Abstract Award from AACC for Evaluation of Sepsis Assay
Cytovale has received an AACC Academy’s Distinguished Abstract Award for its abstract titled “Rapidly Assessing the Host Immune Response for the Diagnosis of Sepsis, a Prospective Multi-Site Clinical Study in the Emergency Department (ED) Employing the Leukocyte Structural Index (LSI).
Forbes | December 16, 2020
Skiing And Snowboarding Go Green - Uphill Or Downhill, New Eco-Friendly Gear
The winter sports industries have been marshalling a lot of green resources in recent years to become more eco-friendly and environmentally conscious, and with ski resorts expected to be at full capacity and record backcountry skiing and snowboarding forecast for this unique pandemic winter of COVID-19, this is more important than ever.
San Francisco Business Times | October 2, 2020
The New Age of Neuro
Many believe that neuroscience is at the same point now that cancer was 20 years ago as new technologies and approaches spawned a revolution in oncology.
Fast Company | September 30, 2020
How WNDR Alpine created skis from algae
This Innovation by Design honoree is engineering new high-performance materials that could help wean a variety of industries off petroleum-based compounds.
GeekWire | September 25, 2020
Seattle gene therapy biotech startup Immusoft raises $4.5M
Seattle-based biotech startup Immusoft raised another $4.5 million and landed a $467,000 NIH grant to help further development of its drugs that treat genetic diseases.
Cortexyme | September 24, 2020
Cortexyme Announces GAIN Trial of Atuzaginstat in Alzheimer’s Disease Has Exceeded Study Enrollment Target of 570 Patients
Cortexyme, Inc. (Nasdaq: CRTX) announced that its GAIN Trial for Alzheimer’s disease (AD) has exceeded its enrollment target of 570 patients. GAIN is a randomized, double-blind, placebo-controlled Phase 2/3 trial of atuzaginstat (COR388), Cortexyme’s lead investigational medicine, in patients with mild to moderate AD.
Checkerspot | August 19, 2020
Checkerspot Closes $36 Million Series B Round
Checkerspot, Inc., a materials innovation company, announced today that it has closed its Series B financing of $36 million. The primary use of proceeds will be directed towards commercial development and the expansion of the company’s product and innovation platform…
TODAY | July 30, 2020
New technology tests common surfaces for presence of coronavirus
The makers of a new coronavirus test say that with a swab you can find out if any surface is contaminated with coronavirus. NBC News investigative and consumer correspondent Vicky Nguyen and her team tried it on surfaces across the country, and the results were revealing.
Opus 12 | June 22, 2020
SoCalGas, PG&E and Opus 12 Announce Advancements in Technology that Converts Carbon Dioxide to Renewable Natural Gas
Southern California Gas Co. (SoCalGas), Pacific Gas and Electric Company (PG&E), and Opus 12 today announced they have demonstrated further advancement of a new electrochemical technology that converts the carbon dioxide content in raw biogas to pipeline-quality renewable natural gas, a critical improvement in the science of upgrading waste emissions to renewable gas.
FDA News | April 27, 2020
BARDA Offers Additional Funding for Cytovale’s Rapid-Sepsis Diagnostic Study
Cytovale has received $3.8 million from HHS’ Biomedical Advanced Research and Development Authority (BARDA) for a study of its rapid-sepsis test for COVID-19 patients. The study is being conducted in Baton Rouge, La., to evaluate the test in patients with potential respiratory infections, including those with SARS-CoV-2.
Bloomberg | April 23, 2020
Using Dust and DNA to Trace Products All the Way Back to the Factory
San Francisco-based Phylagen pledges to bring more transparency to global supply chains.
Garage | April 12, 2020
This Leather Jacket? It Came From a Petri Dish
To visit the vanguard of fashion, one must first manage to find Nutley, New Jersey, on a map; then, a short drive from Manhattan later, after a right turn onto Ideation Way and up the winding drive, one arrives at a hulking, 72,900-square-foot brutalist structure. Welcome to the production headquarters of Modern Meadow…
ShiraTronics | March 26, 2020
ShiraTronics, Inc. Completes $3 Million Additional Series A Financing
ShiraTronics, Inc., a private medical device company, today announced it has completed an additional Series A financing of $3 million bringing the Series A financing to a total of $36 million. The financing was provided by Breakout Ventures (BOV)…
IEEE Spectrum | March 19, 2020
Scientists Can Work From Home When the Lab Is in the Cloud
Working from home is the new normal, at least for those of us whose jobs mostly involve tapping on computer keys. But what about researchers who are synthesizing new chemical compounds or testing them on living tissue or on bacteria in petri dishes? What about those scientists rushing to develop drugs to fight the new coronavirus?…
synbiobeta | March 18, 2020
Running Your Pharma Company Out Of A Starbucks: Drug Discovery Moves To The Cloud
Small biotech start-ups accounted for 63% of all new prescription drug approvals in the last five years. And the way that many big drug companies are establishing their own venture capital funds to invest in small, innovative start-ups, it’s easy to argue that big pharma isn’t doing much innovation these days.
Select Science | January 13, 2020
Eli Lilly and Strateos collaborate to launch remote-controlled robotic cloud lab
Eli Lilly and Company and Strateos, Inc. have unveiled a new robotic laboratory in San Diego, California, designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed by Lilly as part of …
Green Tech Media | December 13, 2019
Watt It Takes: The Founder-Engineer Turning CO2 Into Fuels and Materials
Opus 12 is a team of engineers, electrochemists and materials scientists working on a technology that converts carbon dioxide into usable products. They are developing a metal catalyst that can turn CO2 into synthetic gas for fuels and ethylene for plastics.
Forbes | November 20, 2019
Gore-Tex Is Betting Big On Synthetic Biology
A new era of innovation is taking hold of the outdoor recreation world. It’s happening in high-tech innovation centers in Silicon Valley, in small ski design workshops in Salt Lake City, and in high-tech biology labs in Berkeley.
BioWorld | November 1, 2019
Cytovale scoops up $15M to advance technology that aims to detect early sepsis
Cytovale Inc., a San Francisco-based medical technology company, has picked up $15 million in financing to advance its technology that enables the early detection of sepsis in the emergency department.
Green Biz | October 16, 2019
Opus 12 is one startup on a mission to convert CO2 into useful products
What if excess carbon in the atmosphere could be converted to more useful forms? That’s the ultimate goal of carbon conversion companies such as Opus 12, a startup in Berkeley, California.
Modern Meadow | September 19, 2019
Modern Meadow Secures Strategic Funding From Evonik to Scale the Next Generation of Biofabricated Materials
Over a year into its long-term partnership with global specialty chemicals producer Evonik, Modern Meadow is thrilled to announce it has secured a significant investment from Evonik Venture Capital. This investment will accelerate and support Modern Meadow’s development of its first sustainably produced, animal-free, premium branded materials platform.
Immusoft | July 17, 2019
Immusoft Announces The Appointment Of Robert Hayes, Ph.D. As Chief Scientific Officer
Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced the appointment of Robert Hayes, Ph.D., as Chief Scientific Officer. With nearly two decades of biologics discovery and development experience, Dr. Hayes will lead Immusoft’s preclinical research and …
Cortexyme | May 13, 2019
Cortexyme, Inc. announces closing of initial public offering and the exercise of the underwriters’ option to purchase additional shares
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced…
Synbiobeta | April 16, 2019
Checkerspot raises $13M Series A to produce biotech-enabled performance materials
Checkerspot, a biotech startup using microalgae to produce performance materials, announced today that it has closed its Series A financing for $13 million. The round was led by Builders VC, and included Breakout Ventures…
Fast Company | Feb 14, 2019
This startup is tracking microbes to figure out where your shoes were really made
Because a microbiome can serve as a unique identifier of a place, Phylagen is gathering data from global factories so brands can better understand where their products are made, and detect if the work is being outsourced to places that rely on slavery or child labor….
Science Translational Medicine | Jan 25, 2019
A new infectious mechanism for Alzheimer’s?
We have another entry in the “Is Alzheimer’s caused by infectious disease?” drawing, and it’s a good one. A large multicenter team reports that Porphyromonas gingivalis, which is the key pathogen in gingivitis (gum disease) may be the actual causative agent in Alzheimer’s,…
NewScientist | Jan 23, 2019
We may finally know what causes Alzheimer’s – and how to stop it
After decades of disappointment, we may have a new lead on fighting Alzheimer’s disease. Compelling evidence that the condition is caused by a bacterium involved in gum disease could prove a game-changer in tackling one of medicine’s biggest mysteries, and lead to effective treatments or even a vaccine…
GeekWire | Jan 4, 2019
Seattle biotech startup raises $20M to develop gene therapy technology
Seattle-based biotech startup Immusoft this week closed a $20 million Series B venture capital round that will fuel development of its gene therapy technology. Founded in 2009, Immusoft develops immune cell technology that uses blood cells from a patient to create therapeutic proteins…
Fortune | Sep 17, 2017
These VCs are bringing 'Hard Science' to Fortune 500 companies
In 2010, as the dust from the financial crisis settled, three women working in disparate parts of the economy noticed that startups in “hard science” (think biology or chemistry rather than tech) weren’t getting the attention they deserved from big investors…
TechCrunch | Sep 14, 2017
Breakout Ventures, spun out of Peter Thiel’s Breakout Labs, has closed its debut fund with $60M
Lindy Fishburne has spent most of the last six years heading up Breakout Labs, a San Francisco-based program that’s underwritten by renowned investor Peter Thiel and that in 2011 began offering nascent science-focused startups up to $350,000 in funding with no strings attached…